Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleThe State of the Art

Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy

Fabio Turco, Silke Gillessen, Ken Herrmann, Gaetano Paone and Aurelius Omlin
Journal of Nuclear Medicine May 2025, 66 (5) 665-672; DOI: https://doi.org/10.2967/jnumed.124.267730
Fabio Turco
1Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silke Gillessen
1Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland;
2Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
3Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaetano Paone
2Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland;
4Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelius Omlin
5Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Fabio Turco, Silke Gillessen, Ken Herrmann, Gaetano Paone, Aurelius Omlin
Journal of Nuclear Medicine May 2025, 66 (5) 665-672; DOI: 10.2967/jnumed.124.267730

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Fabio Turco, Silke Gillessen, Ken Herrmann, Gaetano Paone, Aurelius Omlin
Journal of Nuclear Medicine May 2025, 66 (5) 665-672; DOI: 10.2967/jnumed.124.267730
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • HIGH-RISK LOCALIZED DISEASE
    • HIGH-RISK BIOCHEMICAL RECURRENCE
    • MHSPC SETTING
    • GENERAL CRPC
    • NMCRPC
    • POSSIBLE SEQUENCE THERAPIES IN MCRPC
    • TREATMENT OPTIONS AFTER ADT ALONE OR ADT PLUS DOCETAXEL FOR MHSPC
    • TREATMENT OPTIONS AFTER ADT PLUS ARPI FOR MHSPC
    • TREATMENT OPTIONS AFTER ADT PLUS ARPI PLUS DOCETAXEL FOR MHSPC
    • GENERAL CONSIDERATIONS
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Rethinking Dosimetry: A European Perspective
  • A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry
Show more The State of the Art

Similar Articles

Keywords

  • radiopharmaceuticals
  • advanced prostate cancer
  • radiopharmaceutical therapy
  • systemic therapies
  • mCRPC
  • mHSPC
SNMMI

© 2025 SNMMI

Powered by HighWire